Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of $896.86 million. The enterprise value is $822.82 million.
| Market Cap | 896.86M |
| Enterprise Value | 822.82M |
Important Dates
The last earnings date was Tuesday, October 27, 2026, before market open.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 684.01 million shares outstanding. The number of shares has increased by 33.62% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 684.01M |
| Shares Change (YoY) | +33.62% |
| Shares Change (QoQ) | +27.86% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 20.41% |
| Float | 696.57M |
Valuation Ratios
The trailing PE ratio is 45.75 and the forward PE ratio is 30.48.
| PE Ratio | 45.75 |
| Forward PE | 30.48 |
| PS Ratio | 2.35 |
| Forward PS | 2.27 |
| PB Ratio | 3.13 |
| P/TBV Ratio | 5.50 |
| P/FCF Ratio | 26.40 |
| P/OCF Ratio | 25.75 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.68, with an EV/FCF ratio of 24.25.
| EV / Earnings | 34.60 |
| EV / Sales | 2.16 |
| EV / EBITDA | 14.68 |
| EV / EBIT | 16.93 |
| EV / FCF | 24.25 |
Financial Position
The company has a current ratio of 3.23, with a Debt / Equity ratio of 0.39.
| Current Ratio | 3.23 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 1.89 |
| Debt / FCF | 3.32 |
| Interest Coverage | 8.50 |
Financial Efficiency
Return on equity (ROE) is 8.70% and return on invested capital (ROIC) is 15.76%.
| Return on Equity (ROE) | 8.70% |
| Return on Assets (ROA) | 6.37% |
| Return on Invested Capital (ROIC) | 15.76% |
| Return on Capital Employed (ROCE) | 12.46% |
| Weighted Average Cost of Capital (WACC) | 4.40% |
| Revenue Per Employee | $950,243 |
| Profits Per Employee | $59,413 |
| Employee Count | 407 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.76 |
Taxes
In the past 12 months, Pharming Group has paid $10.15 million in taxes.
| Income Tax | 10.15M |
| Effective Tax Rate | 29.56% |
Stock Price Statistics
The stock price has decreased by -15.76% in the last 52 weeks. The beta is 0.05, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | -15.76% |
| 50-Day Moving Average | 10.85 |
| 200-Day Moving Average | 13.56 |
| Relative Strength Index (RSI) | 68.35 |
| Average Volume (20 Days) | 16,400 |
Short Selling Information
The latest short interest is 13,429, so 0.00% of the outstanding shares have been sold short.
| Short Interest | 13,429 |
| Short Previous Month | 20,097 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.44 |
Income Statement
In the last 12 months, Pharming Group had revenue of $386.75 million and earned $24.18 million in profits. Earnings per share was $0.28.
| Revenue | 386.75M |
| Gross Profit | 339.06M |
| Operating Income | 49.42M |
| Pretax Income | 34.33M |
| Net Income | 24.18M |
| EBITDA | 57.01M |
| EBIT | 49.42M |
| Earnings Per Share (EPS) | $0.28 |
Balance Sheet
The company has $189.56 million in cash and $114.51 million in debt, with a net cash position of $75.05 million or $1.10 per share.
| Cash & Cash Equivalents | 189.56M |
| Total Debt | 114.51M |
| Net Cash | 75.05M |
| Net Cash Per Share | $1.10 |
| Equity (Book Value) | 291.24M |
| Book Value Per Share | 4.26 |
| Working Capital | 222.43M |
Cash Flow
In the last 12 months, operating cash flow was $35.37 million and capital expenditures -$870,000, giving a free cash flow of $34.50 million.
| Operating Cash Flow | 35.37M |
| Capital Expenditures | -870,000 |
| Depreciation & Amortization | 7.59M |
| Net Borrowing | -16.17M |
| Free Cash Flow | 34.50M |
| FCF Per Share | $0.50 |
Margins
Gross margin is 87.67%, with operating and profit margins of 12.78% and 6.25%.
| Gross Margin | 87.67% |
| Operating Margin | 12.78% |
| Pretax Margin | 8.88% |
| Profit Margin | 6.25% |
| EBITDA Margin | 14.74% |
| EBIT Margin | 12.78% |
| FCF Margin | 8.92% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -33.62% |
| Shareholder Yield | -33.62% |
| Earnings Yield | 2.19% |
| FCF Yield | 3.79% |
Analyst Forecast
The average price target for Pharming Group is $35.10, which is 170.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.10 |
| Price Target Difference | 170.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 5.70% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharming Group has an Altman Z-Score of 3.9 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.9 |
| Piotroski F-Score | 5 |